IP Library Granted Patent US 8,067,466
Granted Patent B2
US 8,067,466 · App. 12/135,504 · Granted Nov 29, 2011

Cycloalkyl-hydroxyl compounds and compositions for cholesterol management

Assignee: Esperion Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,067,466
App. No.
12/135,504
Granted
Nov 29, 2011
Kind
B2
Abstract

The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Claims (39)

1. A compound having a structure selected from:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable vehicle, excipient, or diluent.

3. The pharmaceutical composition comprising a compound of claim 1 further comprising a second therapeutic agent.

4. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable vehicle, excipient, or diluent which is administered in combination with a statin.

5. A compound according to claim 1 wherein the compound is represented by the formula

or a pharmaceutically acceptable salt thereof.

6. A compound according to claim 1 wherein the compound is represented by the formula

or a pharmaceutically acceptable salt thereof.

7. A compound according to claim 1 wherein the compound is represented by the formula

or a pharmaceutically acceptable salt thereof.

8. A compound according to claim 1 wherein the compound is represented by the formula

or a pharmaceutically acceptable salt thereof.

9. A compound according to claim 1 wherein the compound is represented by the formula

or a pharmaceutically acceptable salt thereof.

10. A compound according to claim 1 wherein the compound is represented by the formula

or a pharmaceutically acceptable salt thereof.

11. A compound according to claim 1 wherein the compound is represented by the formula

or a pharmaceutically acceptable salt thereof.

12. A compound according to claim 1 wherein the compound is represented by the formula

or a pharmaceutically acceptable salt thereof.

13. A compound according to claim 1 wherein the compound is represented by the formula

or a pharmaceutically acceptable salt thereof.

14. A compound according to claim 1 wherein the compound is represented by the formula

or a pharmaceutically acceptable salt thereof.

15. A compound according to claim 1 wherein the compound is represented by the formula

or a pharmaceutically acceptable salt thereof.

16. A compound according to claim 1 wherein the compound is represented by the formula

or a pharmaceutically acceptable salt thereof.

17. A compound according to claim 1 wherein the compound is represented by the formula

or a pharmaceutically acceptable salt thereof.

18. A compound according to claim 1 wherein the compound is represented by the formula

or a pharmaceutically acceptable salt thereof.

19. A compound according to claim 1 wherein the compound is represented by the formula

or a pharmaceutically acceptable salt thereof.

20. A compound according to claim 1 wherein the compound is represented by the formula

or a pharmaceutically acceptable salt thereof.

21. A compound according to claim 1 wherein the compound is represented by the formula

or a pharmaceutically acceptable salt thereof.

Assignments (2)
MERGER Recorded Oct 14, 2014
From: ESPERION THERAPEUTICS, INC.
To: ESPERION THERAPEUTICS, INC.
Reel/Frame 033946/0330 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2011
From: DASSEUX, JEAN-LOUIS HENRI; ONICIU, CARMEN DANIELA
To: ESPERION THERAPEUTICS, INC.
Reel/Frame 027047/0722 →
Continuity (4)
Continuation 11426380 · Jun 26, 2006
Division 10743287 · Dec 23, 2003
Provisional Application 60441795 · Jan 23, 2003
Related Publication 20080249166A1 · Oct 9, 2008